Avid Bioservices Inc (CDMO)

[freethemice]

New study on breast cancer mutations in today's NYT.
http://www.nytimes.com/2012/09/24/health/study-finds-variations-of-breast-cancer.html?ref=global-home
These types of study keep coming out with more and more details of the mutations involved with various
types of cancer. Each time it just reinforces the huge advantage that the MOA of bavituximab has over
the conventional approach of targeting each individual mutation. From today's NYT article.
....
"The study’s biggest surprise involved a particularly deadly breast cancer whose tumor cells resemble basal cells of the skin and sweat glands, which are present in the deepest layer of the skin. These breast basal cells form a scaffolding for milk duct cells. Such cancers are often called triple negative but the study researchers call them basal-like.
Basal-like cancers are most frequent in younger women, in African-Americans and in women with breast cancer genes BRCA1 and BRCA2.
And, the researchers report, their genetic derangements make these cancers a much closer kin of ovarian cancers than of other breast cancers. Basal-like breast cancers also resemble squamous cell cancer of the lung."
....
"For now, despite the tantalizing possibilities, patients will have to wait for clinical trials to see whether drugs that block the genetic aberrations can stop the cancers. And it could be a massive undertaking to get all the drug testing done. Because there are so many different ways a breast cancer cell can go awry, there may have to be dozens of drug studies, each focusing on a different genetic change.
...
There is no reason to expect that bavi would not be just as effective for basal-cell (triple negative) breast cancers,
ovarian cancer, and squamous cell lung cancer. Hopefully bavi will be used in clinical trails for these cancers in the future.